Merck (NYSE: MRK) Q2 2026 Earnings Pre-Day Positioning Ahead of the Tuesday August 4 Before-Market-Open Report With Analyst Focus on Keytruda (Pembrolizumab) Sales Trajectory Ahead of the 2028 US Patent Cliff, the Initial Commercial Ramp of LIPFENDRA (Enlicitide) Oral Macrocyclic Peptide PCSK9 Inhibitor Following the July 16 FDA Approval With Peak Sales Potential of $5 Billion by 2034, Zacks Consensus of $16.33 Billion Revenue and $1.36 Diluted EPS (Down 36.2% Year-Over-Year From $2.13), and Potential 2026 Revenue Guidance Revisions From the Prior $65.8-67 Billion Range
Merck (NYSE: MRK) Q2 2026 earnings pre-day positioning ahead of the Tuesday August 4, 2026 before-market-open report. Zacks analyst consensus: $16.33 billion revenue, $1.36 diluted EPS (down 36.2% year-over-year from $2.13 in Q2 2025). Analyst focus areas: Keytruda (pembrolizumab) sales trajectory (Zacks estimate $8.06 billion Q2, driven by earlier-stage indication uptake and continued metastatic-setting momentum) ahead of the 2028 US patent cliff that ends Keytruda exclusivity; the initial commercial ramp of LIPFENDRA (enlicitide) oral macrocyclic peptide PCSK9 inhibitor following the July 16, 2026 FDA approval, with peak sales potential estimated at $5 billion by 2034 and analyst commentary describing the safety label as 'the cleanest in the class'; contribution from Winrevair (sotatercept for pulmonary arterial hypertension), Welireg (belzutifan for renal cell carcinoma), and Capvaxive (pneumococcal vaccine); and the integration of the Terns Pharmaceuticals and Cidara Therapeutics acquisitions closed in H1 2026. Merck has beaten earnings expectations in each of the trailing four quarters with a 7.75% average earnings surprise; analyst attention also on potential FY 2026 revenue guidance revision from the prior $65.8-67 billion range and non-GAAP EPS guidance from $5.04-5.16.